Close

Gilead (GILD) Terminates Phase 2/3 Study of GS-5745 in Ulcerative Colitis Due to Futility

September 21, 2016 5:01 PM EDT Send to a Friend
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company is stopping its combined Phase 2/3 clinical study of GS-5745 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login